Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Idera Pharma Appoints New CMO

This article was originally published in Scrip

Executive Summary

Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for cancer and rare diseases, has named Dr. Joanna Horobin senior vice president and chief medical officer. Horobin was most recently chief medical officer of Verastem Inc. and previously served as CEO of Syndax Pharmaceuticals. Prior to her positions at Verastem and Syndax, she held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi), where she spearheaded the global oncology business unit’s launches of Taxotere (docetaxel) in breast cancer and Campto/Camptosar (CPT11) for colorectal cancer. Horobin's appointment with Idera will commence on November 30, 2015.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register